Morgan Stanley Issues Positive Forecast for Colgate-Palmolive (NYSE:CL) Stock Price

Colgate-Palmolive (NYSE:CL) had its price target hoisted by analysts at Morgan Stanley from $104.00 to $111.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s target price would suggest a potential upside of 15.12% from the company’s current price.

A number of other equities research analysts have also commented on CL. Royal Bank Of Canada boosted their price objective on shares of Colgate-Palmolive from $104.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday. Jefferies Financial Group reiterated a “hold” rating and set a $89.00 target price (up from $88.00) on shares of Colgate-Palmolive in a report on Monday, August 3rd. Barclays increased their target price on Colgate-Palmolive from $80.00 to $87.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. BNP Paribas Exane cut their price target on Colgate-Palmolive from $101.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, September 28th. Finally, Bank of America boosted their price target on Colgate-Palmolive from $100.00 to $105.00 and gave the company a “buy” rating in a report on Monday. Thirteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, Colgate-Palmolive currently has a consensus rating of “Moderate Buy” and an average target price of $100.78.

Colgate-Palmolive Stock Up 1.2%

CL stock traded up $1.13 during mid-day trading on Monday, hitting $96.42. 1,565,734 shares of the company were exchanged, compared to its average volume of 5,625,901. The company has a debt-to-equity ratio of 13.82, a quick ratio of 0.30 and a current ratio of 0.46. The firm has a market cap of $76.86 billion, a P/E ratio of 37.77, a P/E/G ratio of 4.59 and a beta of 0.31. The firm’s 50 day simple moving average is $89.54 and its 200 day simple moving average is $89.65. Colgate-Palmolive has a 1-year low of $74.54 and a 1-year high of $99.33.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.34 billion. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.91 earnings per share. On average, sell-side analysts predict that Colgate-Palmolive will post 3.89 EPS for the current fiscal year.

Insider Transactions at Colgate-Palmolive

In related news, CEO Noel R. Wallace sold 161,021 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $91.92, for a total transaction of $14,801,050.32. Following the sale, the chief executive officer owned 362,231 shares in the company, valued at approximately $33,296,273.52. This represents a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John T. Cahill sold 4,170 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total value of $389,352.90. Following the transaction, the director directly owned 28,373 shares of the company’s stock, valued at $2,649,187.01. This trade represents a 12.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,191 shares of company stock worth $16,110,903 in the last three months. Insiders own 0.43% of the company’s stock.

Institutional Investors Weigh In On Colgate-Palmolive

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virginia Estate & Retirement Planning Advisors Inc. grew its stake in shares of Colgate-Palmolive by 1,409.1% in the third quarter. Virginia Estate & Retirement Planning Advisors Inc. now owns 332 shares of the company’s stock valued at $28,000 after buying an additional 310 shares in the last quarter. Parvin Asset Management LLC bought a new stake in Colgate-Palmolive during the second quarter worth $32,000. Park Place Capital Corp raised its position in Colgate-Palmolive by 55.5% during the second quarter. Park Place Capital Corp now owns 356 shares of the company’s stock worth $33,000 after acquiring an additional 127 shares in the last quarter. Cherry Tree Wealth Management LLC lifted its stake in Colgate-Palmolive by 7,840.0% in the second quarter. Cherry Tree Wealth Management LLC now owns 397 shares of the company’s stock valued at $36,000 after acquiring an additional 392 shares during the last quarter. Finally, Montgomery Financial Services LLC acquired a new stake in Colgate-Palmolive in the second quarter valued at $36,000. Institutional investors own 80.41% of the company’s stock.

More Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Better-than-expected quarterly results: Colgate-Palmolive reported third-quarter earnings of $0.97 per share, above the $0.93 consensus estimate, while revenue rose 4.6% year over year to $5.37 billion, slightly exceeding expectations. Colgate-Palmolive Analysts Boost Their Forecasts After Upbeat Q3 Earnings
• Positive Sentiment: Improved outlook: Management narrowed its 2026 sales outlook while raising its margin and earnings-per-share guidance, signaling improved confidence in profitability and supporting the positive market reaction. Colgate-Palmolive sales rise 4.6% and it lifts margin and EPS outlook
• Positive Sentiment: Analyst target increases: RBC raised its price target from $104 to $105 and maintained an “outperform” rating. Wells Fargo also increased its target from $90 to $95, despite retaining an “equal weight” rating.
• Neutral Sentiment: Mixed analyst signals: JPMorgan lowered its target from $104 to $102 but kept an “overweight” rating, while Barclays maintained a “hold” rating. These actions suggest continued confidence in the business but limited near-term upside at the current valuation.
• Negative Sentiment: Lingering profit concerns: Commentary following the earnings report noted that questions remain about profit growth, which could restrain further gains if cost pressures or weaker-than-expected margins emerge. Colgate Palmolive Stock Climbs After Q3 Earnings Yet Profit Questions Linger

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.